Clinical trial
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
NCT04977453
Study timeline
Study start (actual)2021-08-02Date precision: day
Registry last updated2026-09-14
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Advanced Solid Tumorunresolved
Metastatic Solid Tumorunresolved
Cervical Cancerunresolved
Urothelial Carcinomaunresolved
Clear Cell Renal Cell Cancer (ccRCC)unresolved
Squamous Cell Non Small Cell Lung Cancerunresolved
Interventions
Sponsors & collaborators
GI Innovation, Inc.lead sponsor
Merck Sharp & Dohme LLCcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04977453 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.